Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Rigel Announces Poster Presentations at FOCIS Annual Meeting


SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting in San Francisco, June 20-23, 2018. 

Poster presentation details:
Thursday, June 21st, 6:25?7:30pm PDT
Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor, in Adult Persistent/Chronic Immune Thrombocytopenia (ITP): Safety and Efficacy Results From Patients Who Converted From Placebo Onto the 049 Open-Label Extension Study
Poster Number: T.96
Abstract Number: 450284

Poster presentation details:
Friday, June 22nd, 6:15?7:30pm PDT
Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Preliminary Results of the SOAR Phase 2, Multicenter, Open-Label Study
Poster Number: F.98
Abstract Number: 449169

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSEtm (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Please see www.TAVALISSE.com for full Prescribing Information.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: [email protected]

Media Contact: Jessica Daitch
Phone: 917.816.6712
Email: [email protected]

Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

 

SOURCE Rigel Pharmaceuticals, Inc.


These press releases may also interest you

at 18:00
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plustm, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:50
Cantaloupe, Inc. to Report Third Quarter Fiscal Year 2024 Results on May 9, 2024
Cantaloupe, Inc. , a leading provider of end-to-end technology solutions for self-service commerce, today announced that management will host a webcast to discuss its financial results for the third quarter of fiscal year 2024 on Thursday, May 9,...

at 17:31
DRI Healthcare Trust Closes Previously Announced Refinancing of Preferred Securities
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...

at 17:21
TRAM VF Announces Flagship Investment in London Ride-Hailing Startup, OUNO
Tri Ri Asset Management ("TRAM") is pleased to announce a strategic investment from its flagship venture capital fund, the TRAM Venture Fund ("TRAM VF"), in OUNO, a pioneering executive ride-hailing platform headquartered in London. This...

at 17:20
Melanie McFaddin with Wiley Bros ? Aintree Capital &Partners, LLC Represents Theoris, Inc. in its Acquisition by CoreTech Consulting Group, LLC
Melanie McFaddin, representative of Wiley Bros ? Aintree Capital &Partners, LLC ("WBAC") is pleased to announce its representation of Theoris, Inc. ("Theoris" and the "Company") in its sale to CoreTech Consulting Group, LLC ("CoreTech"). Theoris'...

at 17:16
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Sharecare Inc. to Contact Law Firm
Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Sharecare...

More news about Science and technology...


News published on and distributed by: